| 產(chǎn)品名稱 |
HCC1395 |
| 商品貨號(hào) |
B164556 |
| Organism |
Homo sapiens, human |
| Tissue |
mammary gland; breast/duct |
| Cell Type |
Epithelial, lymphoblast |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
TNM stage I, grade 3, primary ductal carcinoma |
| Age |
43 years adult |
| Gender |
female |
| Ethnicity |
Caucasian, White |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
polyploid |
| Derivation |
This cell line was initiated on 12/14/94 from a patient with a family history of cancer (patient's mother had breast cancer). The cell line took 14 months to establish. |
| Clinical Data |
female
43 years
Caucasian, White
An EBV transformed lymphoblastoid cell line (HCC1395BL) from the same patient is available as ATCC CRL-2325. |
| Receptor Expression |
estrogen receptor, negative according to depositor progesterone receptor, negative |
| Oncogene |
her2/neu -, p53 + |
| Genes Expressed |
Epithelial glycoprotein 2 (EGP2),cytokeratin 19 |
| Cellular Products |
Epithelial glycoprotein 2 (EGP2) cytokeratin 19 |
| Comments |
The tumor was classified as TNM stage I, grade 3, invasive ductal carcinoma with 0 out of 34 lymph node metastasis.
The cells are poorly differentiated and vacuolated.?
The cells are negative for expression of Her2-neu but positive for expression of p53.
HCC1395 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptors (ER -) according to depositor and negative for expression of progesterone receptors (PR -).
An EBV transformed lymphoblastoid cell line (HCC1395BL) from the same patient is available as ATCC CRL-2325.
|
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C
Subculture Ratio: 1:2
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
|
| Cryopreservation |
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile |
Amelogenin: X CSF1PO: 11 D13S317: 9 D16S539: 11 D5S818: 11 D7S820: 10,12 THO1: 9.3 TPOX: 11 vWA: 15 |
| Name of Depositor |
AF Gazdar, AK Virmani |
| Year of Origin |
December 14, 1994 |
| References |
Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
|
